Curriculum Vitae - Istituto di Ricerche Farmacologiche Mario Negri

Curriculum Vitae Europass
Informazioni personali
Nome / Cognome Roberto Latini
Via Leone Pancaldo, 1/3 - 20129 Milano (Italia)
Indirizzo
Telefono +39 02 39014454
Cellulare: +39 3396092097
Fax +39 02 33200049
E-mail [email protected]
Cittadinanza Italiana
Data di nascita 15/12/1951
Sesso Maschile
Esperienza professionale
Dal Marzo 2013 ad oggiCapo del Dipartimento di Ricerca Cardiovascolare, IRCCS Istituto di Ricerche
Farmacologiche “Mario Negri”, Milano
Dal 1991 ad oggi Membro dei Comitati Direttivi degli studi clinici multicentrici: ALOFT, ValHeft, GISSI-HF,
GISSI-AF, CANDHEART, CYCLE, ICOS-ONE
Dal 1990 ad oggiCapo del Laboratorio di Farmacologia Clinica Cardiovascolare, Dipartimento di Ricerca
Cardiovascolare, IRCCS Istituto di Ricerche Farmacologiche “Mario Negri”, Milano
1999-2009 Visiting Professor, Department of Medicine, New York Medical College, Valhalla, NY,
USA.
Dal 1981-1983Cardiology Fellow (Robert E. Kates laboratory), Stanford University Medical Center,
CA, USA.
Dal 1973-1990Ricercatore presso il Laboratorio di Farmacologia Clinica, Istituto di Ricerche
Farmacologiche “Mario Negri”, Milano
Nome e indirizzo del datore di IRCCS Istituto di Ricerche Farmacologiche “Mario Negri”
lavoro Via La Masa, 19 20156 Milano, Italia
Tipo di attività o settore Ricercatore
Istruzione e formazione
Date 1978
Titolo della qualifica rilasciata Laurea in Medicina e Chirurgia
Nome e tipo d'organizzazione Università di Milano
erogatrice dell'istruzione e
formazione
Pagina 1/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Capacità e competenze
personali
Madrelingua(e) Italiano
Altra(e) lingua(e) Inglese - Francese
Autovalutazione
Comprensione
Livello europeo (*)
Ascolto
Lettura
Parlato
Interazione
Produzione
orale
orale
Inglese C2
C2
C2
C2
Francese C2
C2
B2
B2
(*) Quadro comune europeo di riferimento per le lingue
Scritto
C2
C2
Capacità e competenze sociali Spirito di gruppo
Buone capacità di comunicazione nell’ambito lavorativo
Capacità e competenze Adeguate al ruolo lavorativo
organizzative
Capacità e competenze tecniche Attività Scientifica
- circa 250 pubblicazioni su riviste internazionali peer-reviewed
- partecipazioni a congressi scientifici nazionali e internazionali in qualità di
relatore
- revisore per varie riviste cardiologiche internazionali
Attuali campi di ricerca
- meccanismi di danno cardiaco conseguenti all’infarto miocardico acuto, in
particolare quelli legati all’attivazione neurormonale;
- utilizzo di cellule staminali per limitare il danno strutturale e funzionale derivante
da infarto miocardico nel piccolo roditore.
Capacità e competenze Buone conoscenze dei programmi Office; corso di base di programmazione in Pascal
informatiche (Stanford University 1983).
Patente Automobilistica,Nautica tipo B, radiotelefonia onde medie
Allegati PUBBLICAZIONI
Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30
giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".
Firma
Milano, 18-09-2014
Pagina 2/12 - Curriculum vitae di
Roberto Latini
Dr. Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
PUBBLICAZIONI
Askevold ET, Aukrust P, Nymo SH , Lunde IG, Kaasbøll OJ, Aakhus S, Florholmen G, Ohm IK, Strand ME, Attramadal H,
Fiane A, Dahl CP, Finsen AV, Vinge LE, Christensen G, Yndestad A, Gullestad L, Latini R, Masson S, Tavazzi L, GISSIHF Investigators, Ueland T
The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure
J Intern Med 2014; 275: 621-630
Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G,
Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L, for the ALBIOS Study Investigators
Albumin replacement in patients with severe sepsis or septic shock
New Engl J Med 2014; 370: 1412-1421
Cannone V, Barlera S, Pileggi S, Masson S, Franzosi MG, Latini R, Scardulla C, Clemenza F, Maggioni AP, Nicolosi GL,
Tavazzi L, Burnett JC Jr, GISSI-HF Investigators
The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure
Int J Cardiol 2014; Epub
Fumagalli F, Russo I, Staszewsky L, Li Y, Letizia T, Masson S, Novelli D, Rocchetti M, Canovi M, Veglianese P, Gobbi M,
Latini R, Zaza A, Ristagno G
Ranolazine ameliorates post-resuscitation electrical instability and myocardial dysfunction and improves survival with
good neurological recovery in a rat model of cardiac arrest
Heart Rhythm 2014; 11: 1641-1647
Guzzetti S, Bassani T, Latini R, Masson S, Barlera S, Citerio G, Porta A
Autonomic cardiovascular modulation with three different anesthetic strategies during neurosurgical procedures
Minerva Anestesiol 2014, Epub
Latini R, Masson S
Circulating cardiac biomarkers and outcome. Chapter 20
In: Gullo A, Ristagno G (eds) Resuscitation. Springer-Verlag Italia Milano, 2014; 211-217
Masson S, Agabiti N, Vago T, Miceli M, Mayer F, Letizia T, Wienhues-Thelen U, Mureddu GF, Davoli M, Boccanelli A,
Latini R, on behalf of the Investigators of the PREDICTOR Study
The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk
J Intern Med 2014; Epub
Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, Fumagalli R, Mauri T, Isgrò S, Fanizza C,
Romero M, Tognoni G, Latini R, Gattinoni L
Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian
Outcome Sepsis trial
Crit Care 2014; 18: R6
Nobili A, Pasina L. Latini R
Beta-adrenoceptor antagonists and antianginal drugs. Chapter 18
In: Aronson JK, Side Effects of Drugs. Annual 35
Elsevier, Amsterdam 2014; 351-357
Palazzuoli A, Masson S, Ronco C, Maisel M
Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin
Heart Fail Rev 2014; 19: 267-284
Ristagno G, Fumagalli F, Russo I, Tantillo S, Zani D D, Locatelli V, De Maglie M, Novelli D, Staszewsky L, Vago T, Belloli
A, Di Giancamillo M, Fries M, Masson S, Scanziani E, Latini R
Postresuscitation treatment with argon improves early neurological recovery in a porcine model of cardiac arrest
Shock 2014: 41: 72-78
Ristagno G, Latini R, Vaahersalo J, Masson S, Kurola J, Varpula T, Lucchetti J, Fracasso C, Guiso G, Montanelli A,
Barlera S, Gobbi M, Tiainen M, Pettilä V, Skrifvars MB, for the FINNRESUSCI Investigators
Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from outof-hospital cardiac arrest
J Am Heart Assoc 2014; 3:e001094
Pagina 3/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Rocchetti M, Sala L, Rizzetto R, Staszewsky L, Alemanni M, Zambelli V, Russo I, Barile L, Cornaghi L, Altomare C,
Ronchi C, Mostacciuolo G, Lucchetti J, Gobbi M, Latini R, Zaza A
Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension
Cardiovasc Res 2014 Epub
Schäfer Hackenhaar F, Fumagalli F, Li Volti G, Sorrenti V, Russo I, Staszewsky L, Masson S, Latini R, Ristagno G
Relationship between post-cardiac arrest myocardial oxidative stress and myocardial dysfunction in the rat
J Biomed Sci 2014, 21: 70
Sud S, Friedrich JO, Adhikari NKJ, Taccone P, Mancebo J, Polli F, Latini R, Pesenti A, Curley MAQ, Fernandez R, Chan
M-C, Beuret P, Voggenreiter G, Sud M, Tognoni G, Gattinoni L, Guérin C
Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress
syndrome: a systematic review and meta-analysis
CMAJ 2014; 186: E381-E390
Aleksova A, Masson S, Maggioni AP, Lucci D, Fabbri G, Beretta L, Mos L, Paino AM, Nicolosi GL, Marchioli R, Tognoni
G, Tavazzi L, Sinagra G, Latini R, on behalf of the GISSI-Heart Failure (GISSI-HF) Investigators
n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial
Eur J Heart Fail 2013; 15: 1289-1295
Amigoni M, Bellani G, Zambelli V, Scanziani M, Farina F, Fagnani L, Latini R, Fumagalli R, Pesenti A
Unilateral acid aspiration augments the effects of ventilator lung injury in the contralateral lung
Anesthesiology 2013; 119: 642-651
Aspromonte N, Di Fusco S A, Latini R, Cruz D N, Masson S, Tubaro M, Palazzuoli A
Natriuretic peptides in acute chest pain and acute coronary syndrome: from pathophysiology to clinical and prognostic
applications
Coron Artery Dis 2013; 24: 33-39
Brunelli L, Ristagno G, Bagnati R, Fumagalli F, Latini R, Fanelli R, Pastorelli R
A combination of untargeted and targeted metabolomics approaches unveils changes in the kynurenine pathway
following cardiopulmonary resuscitation
Metabolomics 2013; 9: 839-852
Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, Proietti G, Barbuzzi S, Nicolosi GL,
Tavazzi L, Maggioni AP, Latini R
Tubular damage and worsening renal function in chronic heart failure
J Am Coll Cardiol HF 2013; 1: 417-424
Disertori M, Franzosi M G, Barlera S, Cosmi F, Quintarelli S, Favero C, Cappellini G, Fabbri G, Maggioni A P, Staszewsky
L, Moroni L A, Latini R, on behalf of the GISSI-AF Investigators
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial
BMC Cardiovasc Disord 2013; 13: 28
Latini R, Masson S
Significance of measurable cardiac troponin by high-sensitivity assays in patients with chronic stable heart failure
Coron Artery Dis 2013; 24: 716-719
Latini R, Masson S
NT-proBNP: a guide to improve the management of patients with heart failure
eJIFCC 2013; 24: (n 3-4) 1-7
Latini R, Staszewsky L, Sun J, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F , Giles TD, Maggioni AP,
Rutten GEHM , Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJV
Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and
other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes
Research trial
Am Heart J 2013; 166: 935-940.e1
La Rovere MT, Staszewsky L, Barlera S, Mezzani A, Midi P, Marchioli R, Maggioni AP, Tognoni G, Tavazzi L, Latini R, on
behalf of the GISSI-HF Investigators
n-3PUFA and holter derived autonomic variables in heart failure patients: Data from the Gruppo Italiano per lo Studio
della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter Substudy
Pagina 4/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Heart Rhythm 2013; 10: 226-232
Lesogor A, Cohn J N, Latini R, Tognoni G, Krum H, Zalewski A, Kandra A, Hua T A, Gimpelewicz C
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system
blockade in patients with heart failure: insights from the Val-HeFT study
Eur J Heart Fail 2013; 15: 1236-1244
Masson S, Latini R, Cioffi G, Urso R, Vago T, Lucci D, Mureddu G F, Tarantini L, Faggiano P, Girfoglio D, Velussi M,
Maggioni AP, Giorda CB, Comaschi M, DYDA Investigators
Cardiovascular biomarkers, cardiac dysfunction, and outcomes in patients with type 2 diabetes: A prospective,
multicenter study
Diabetes Care 2013; 36: e137-e138
Masson S, Latini R, Mureddu GF, Agabiti N, Miceli M, Cesaroni G, Forastiere F, Wienhues-Thelen U-H, Block D, Zaugg
C, Vago T, Boccanelli R, on behalf of the Investigators of the PREDICTOR study
High-sensitivity cardiac troponin T for detect subtle abnormalities of cardiac phenotype in a general population of elderly
individuals
J Inter Med 2013; 273:306-317
Masson S, Marchioli R, Mozaffarian D, Bernasconi R, Milani V, Dragani L, Tacconi MT, Marfisi R M, Borgese L,
Cirrincione V, Febo O, Nicolis E, Maggioni AP, Tognoni G, Tavazzi L, Latini R, GISSI-HF Investigators
Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial. Relation with fish intake,
circulating biomarkers, and mortality
Am Heart J 2013;165:208-215.e4
Mozaffarian D, Wu JHY, de Oliveira Otto MC , Sandesara CM, Metcalf RG, Latini R, Libby P, Lombardi F, O'Gara PT,
Page RL, Silletta MG, Tavazzi L, Marchioli R
Fish oil and post-operative atrial fibrillation. A meta-analysis of randomized controlled trials
J Am Coll Cardiol 2013; 61: 2194-2196
Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, Cesaroni G, Miceli M, Forastiere F, Scardovi AB,
Uguccioni M, Boccanelli A
Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart
failure in the elderly. Results from "PREDICTOR", a population based-study in central Italy
Eur J Heart Fail 2013; 15: 1102-1112
Olivieri F, Antonicelli R, Recchioni R, Mariotti S , Marcheselli F, Lisa R, Spazzafumo L, Galeazzi R, Caraceni D, Testa R,
Latini R, Procopio AD
Telomere/telomerase system impairment in circulating angiogenic cells of geriatric patients with heart failure
Int J Cardiol 2013; 164: 99-105
Raimondi M T, Balconi G, Boschetti F, Di Metri A, Mohammed SAA, Quaglini V, Araneo L, Galvez BG, Lupi M, Latini R,
Remuzzi A
An opto-structural methods to estimate the stress-strain field induced by cell contraction on substrates of controlled
stiffness in vitro
J Appl Biomater Function Mater 2013; 11: 143-150
Ristagno G, Fries M, Brunelli L, Fumagalli F, Bagnati R, Russo I, Staszewsky L, Masson S, Li Volti G, Zappalà A, Derwall
M, Brücken A, Pastorelli G, Latini R
Early kynurenine pathway activation following cardiac arrest in rats, pigs, and humans
Resuscitation 2013; 84: 1604-1610
Sciorati C, Staszewsky L, Zambelli V, Russo I, Salio M, Novelli D, Di Grigoli G, Moresco R M, Clementi E, Latini R
Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure
Pharmacological Research 2013; 73:35-43
Staszewsky L, Latini R
What is the atrium trying to tell us?
Eur Heart J 2013; 34: 255-257
Talan MI, Latini R
Myocardial infarction: cardioprotection by erythropoietin
Methods Mol Biol 2013; 982: 265-302
Pagina 5/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Ueland T, Nymo SH , Latini R, McMurray JJV, Kjekshus J, Yndestad A, Fucili A, Grosu A, Masson S, Maggioni AP,
Gullestad L, Aukrust P, on behalf of the Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure
(CORONA), GISSI-Heart Failure (GISSI-HF) trials
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials
Eur J Heart Fail 2013; 15; 747-755
Wu JHY, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS, Masson S, Latini R, Albert C, Brown NJ,
Lamarra M, Favaloro RR, Mozaffarian D
Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA Trial
J Am Heart Assoc 2013; 2: e000397
Aleksova A, Masson S, Maggioni AP, Lucci D, Urso R, Staszewsky L, Ciaffoni S, Cacciatore G, Misuraca G, Gulizia M,
Mos L, Proietti G, Minneci C, Latini R, Sinagra G, CandHeart Investigators
Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure
Cardiovasc Drugs Ther 2012; 26: 131-143
Bernal A, San Martin N, Fernández M, Covarello D, Molla F, Soldo A, Latini R, Cossu G, Galvez BG
L-selectin and SDF-1 enhance the migration of mouse and human cardiac mesoangioblasts
Cell Death Differ 2012; 19: 345-355
Citerio G, Pesenti A, Latini R, Masson S, Barlera S, Gaspari F, Franzosi MG, NeuroMorfeo Study Group
A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia
during elective craniotomy
Eur J Anaesthesiol 2012; 29: 371-379
Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG
Systematic review and meta-analysis: Renin-angiotensin system inhibitors in the prevention of atrial fibrillation
recurrences. An unfulfilled hope
Cardiovasc Drugs Ther 2012; 26: 47–54
Ferratini M, Ripamonti V, Masson S, Grati P, Racca V, Cuccovillo I, Raimondi E, Capomolla S, Macchi C, Coruzzi P,
Vago T, Calvo M, Mantovani A, Latini R
Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac
surgery patients
J Cardiopulm Rehabil Prev 2012; 32: 17-24
Franzosi MG, Latini R
Beta-adrenoceptor antagonists and antianginal drugs. Chapter 18
In: Aronson JK, Side Effects of Drugs. Annual 34
Elsevier, Amsterdam 2012, 303-310.
Latini R, Gullestad L, Masson S, Nymo SH , Ueland T, Cuccovillo I, Vårdal M , Bottazzi B, Mantovani A, Lucci D, Masuda
N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L, on behalf of the Investigators of the Controlled Rosuvastatin
Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trial
Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
Eur J Heart Fail 2012; 14: 992-999
Masson S, Anand I S, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R,
on behalf of the Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza
nell’Insufficienza Cardiaca-Heart Failure ( GISSI-HF) Investigators
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure. Data from 2
large randomized clinical trials
Circulation 2012; 125: 280-288
Meda C, Molla F, De Pizzol M, Regano D, Maione F, Capano S, Locati M, Mantovani A, Latini R, Bussolino F, Giraudo E
Semaphorin 4A exerts a proangiogenic effect by enhancing vascular endothelial growth factor-A expression in
macrophages
J Immunol 2012; 188: 4081-4092
Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT,
Page RL, Tavazzi L, Tognoni G, for the OPERA Investigators.
Pagina 6/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation
(OPERA) randomized trial
JAMA 2012; 308: 2001-2011
Burba I, Colombo GI, Staszewsky LI, De Simone M, Devanna P, Nanni S, Avitabile D, Molla F, Cosentino S, Russo I, De
Angelis N, Soldo A, Biondi A, Gambini E, Gaetano C, Farsetti A, Pompilio G, Latini R, Capogrossi MC, Pesce M
Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34+ cells
PLoS One 2011; 6: e22158
Cioffi G, Faggiano P, Lucci D, Di Lenarda A, Mureddu GF, Tarantini L, Verdecchia P, Comaschi M, Giorda CB, Velussi M,
Chinali M, Latini R, Masson S, De Simone G, DYDA Investigators
Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The
DYDA study
J Hypertens 2011; 29: 1994-2003
Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F,
Tognoni G, Tavazzi L, Latini R
Clinical outcome of renal tubular damage in chronic heart failure
Eur Heart J 2011; 32: 2705–2712
de Simone G, Chinali M, Mureddu GF, Cacciatore G, Lucci D, Latini R, Masson S, Vanasia M, Maggioni AP, Boccanelli A,
AREA IN-CHF Investigators
Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The
AREA-IN-CHF study
Nutr Metab Cardiovasc Dis 2011; 21: 783-791
Disertori M, Lombardi F, Barlera S, Maggioni AP, Favero C, Franzosi MG, Lucci D, Staszewsky L, Fabbri G, Quintarelli S,
Bianconi L, Latini R
Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio
della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial
Am Heart J 2011; 162: 382-389
Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, Favero C, Franzosi MG, Serra D, Lucci D, Bianchini F,
Bernasconi R, Maggioni AP, Nicolosi GL, Porcu M, Tognoni G, Tavazzi L, Marchioli R
Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and
implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza
nell'Insufficienza Cardiaca (GISSI-HF) trial
Am Heart J 2011; 161: 338-343.e1
Franzosi MG, Latini R
Beta-adrenoceptor antagonists and antianginal drugs. Chapter 18
In: Side effects of drugs. Annual 33.
Elsevier, Amsterdam, 2011; 397-406
Giorda CB, Cioffi G, de Simone G, Di Lenarda A, Faggiano P, Latini R, Lucci D, Maggioni AP, Tarantini L, Velussi M,
Verdecchia P, Comaschi M, DYDA Investigators
Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study
Eur J Cardiovasc Prev Rehabil 2011; 18: 415-423
Gunetti M, Noghero A, Molla F, Staszewsky LI, De Angelis N, Soldo A, Russo I, Errichiello E, Frasson C, Rustichelli D,
Ferrero I, Gualandris A, Berger M, Geuna M, Scacciatella P, Basso G, Marra S, Bussolino F, Latini R, Fagioli F
Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies
Cytotherapy 2011; 13: 1140-1152
Latini R, Masson S, Pirelli S, Barlera S, Pulitano' G, Carbonieri E, Gulizia M, Vago T, Favero C, Zdunek D, Struck J,
Staszewsky L, Maggioni AP, Franzosi MG, Disertori M, GISSI-AF Investigators
Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial
J Intern Med 2011; 269: 160-171
Masson S, Gori F, Latini R, Milani V, Flyvbjerg A, Frystyk J, Crociati L, Pietri S, Vago T, Barlera S, Maggioni AP, Tognoni
G, Tavazzi L, Omland T, Franzosi MG, GISSI-HF Investigators
Adiponectin in chronic heart failure: influence of diabetes and genetic variants
Eur J Clin Invest 2011; 41: 1330-1338
Pagina 7/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Mozaffarian D, Marchioli R, Gardner T, Ferrazzi P, O'Gara P, Latini R, Libby P, Lombardi F, Macchia A, Page R, Santini
M, Tavazzi L, Tognoni G, Masson S
The ω-3 fatty acids for prevention of post-operative atrial fibrillation trial—rationale and design
Am Heart J 2011; 162: 56-63.e3
Pitt B, Latini R, Maggioni AP, Solomon SD, Smith BA, Wright M, Prescott MF, McMurray JJV
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor
antagonist: the Aliskiren Observation of Heart Failure Treatment study
Eur J Heart Fail 2011; 13: 755-764
Riess I, Sala V, Leo C, Demaria M, Gatti S, Gallo S, Fitou A, Boero O, Levi R, Cuccovillo I, Molla F, De Angelis N,
Staszewsky L, Latini R, Crepaldi T
A mouse model for spatial and temporal expression of HGF in the heart
Transgenic Res 2011; 20: 1203–1216
Scanziani M, Amigoni M, Bellani G, Zambelli V, Masson S, Radaelli E, Pesenti A, Latini R
The effect of a single bolus of exogenous surfactant on lung compliance persists until two weeks after treatment in a
model of acid aspiration pneumonitis
Pulm Pharmacol Ther 2011; 24: 141-146
Sidik NP, Solomon SD, Latini R, Maggioni AP, Wright M, Gimpelewicz CR, Pitt B, McMurray JJV
Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of
the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial
Cardiovasc Drugs Ther 2011; 25: 315-321
Staszewsky L, Wong M, Masson S, Raimondi E, Gramenzi S, Proietti G, Bicego D, Emanueli C, Pulitano' G, Taddei F,
Nicolis EB, Correale E, Fabbri G, Bertocchi C, Franzosi MG, Maggioni AP, Tognoni G, Disertori M, Latini R, GISSI-AF
Investigators
Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF
echocardiographic substudy
Circ Cardiovasc Imaging 2011; 4: 721-728
Zambelli V, Santaniello A, Fumagalli F, Masson S, Scorza R, Beretta L, Latini R
Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension
Eur J Pharmacol 2011; 667: 287-291
Aspromonte N, Di Tano G, Latini R, Masson S, Valle R, Emdin M
Ruolo dei biomarcatori per la stratificazione prognostica e la personalizzazione del follow-up nel paziente con
scompenso cardiaco
G Ital Cardiol 2010; 11: 17s-23s
Disertori M, Lombardi F, Barlera S, Latini R, Maggioni AP, Zeni P, Di Pasquale G, Cosmi F, Franzosi MG, on behalf of
the GISSI-AF Investigators
Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto
Miocardico–Atrial Fibrillation (GISSI-AF) trial
Am Heart J 2010; 159: 857-863
Franzosi MG, Latini R
Beta-adrenoceptor antagonists and antianginal drugs
In: Side effects of drugs. Annual 32.
Elsevier, Amsterdam, 2010; 363-369
Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W, Cavaletti G, Cerami A, Chopp M, Coleman T,
Digicaylioglu M, Ehrenreich H, Erbayraktar S, Erbayraktar Z, Gassmann M, Genc S, Gokmen N, Grasso G, Juul S, Lipton
SA, Hand CC, Latini R, Lauria G, Leist M, Newton SS, Petit E, Probert L, Sfacteria A, Siren AL, Talan M, Thiemermann
C, Westenbrink D, Yaqoob M, Zhu C.
Erythropoietin: not just about erythropoiesis
Lancet 2010; 375: 2142
Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni AP,
Tavazzi L, for the GISSI-HF Investigators
Pagina 8/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a
substudy of GISSI-HF trial
Eur J Heart Fail 2010; 12: 1345-1353
Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, Cioffi G, Sinagra G, Mazzone C, Bertocchi
F, Vago T, Peri G, Cuccovillo I, Masuda N, Barlera S, Mantovani A, Maggioni AP, Franzosi MG, Disertori M, Latini R, on
behalf of the GISSI-AF Investigators
Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for
atrial fibrillation: data from the GISSI atrial fibrillation trial
Heart 2010; 96: 1909-1914
Masson S, Latini L, Milani V, Moretti L, Rossi MG, Carbonieri E, Frisinghelli A, Minneci C, Valisi M, Maggioni AP,
Marchioli R, Tognoni G, Tavazzi L, on behalf of the GISSI-HF Investigators
Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic HF. Data from the GISSIHeart Failure (GISSI-HF) trial
Circ Heart Fail 2010; 3: 65-72
Masson S, Latini R, Anand IS
An update on cardiac troponins as circulating biomarkers in heart failure
Curr Heart Fail Rep 2010; 7: 15-21
Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A,
Maggioni AP, Tognoni G, Tavazzi L, on behalf of the GISSI-HF Investigators
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from
the GISSI-heart failure (GISSI-HF) trial
Eur J Heart Fail 2010; 12: 338-347
Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN, on behalf of the
Val-HeFT Investigators
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy:
Data from the Valsartan Heart Failure trial (Val-HeFT)
J Card Fail 2010; 16: 964-970
Mauri T, Masson S, Pradella A, Bellani G, Coppadoro A, Bombino M, Valentino S, Patroniti N, Mantovani A, Pesenti A,
Latini R
Elevated plasma and alveolar levels of soluble receptor for advanced glycation endproducts are associated with severity
of lung dysfunction in ARDS patients
Tohoku J Exp Med 2010; 222: 105-112
Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT, Revera M, Mezzani A, Tognoni G, Tavazzi L, Omland
T, on behalf of the GISSI-HF Investigators
Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial
Eur J Heart Fail 2010; 12: 549-556
Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Misuraca G, Maggioni AP, Tognoni G,
Tavazzi L, Latini R, on behalf of the GISSI-HF Investigators
Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial
Am Heart J 2010; 160: 286-293
Sud S, Friedrich J O, Taccone P, Polli F, Adhikari NKJ, Latini R, Pesenti A, Guérin C, Mancebo J, Curley MAQ,
Fernandez R, Chang MC, Beuret P, Voggenreiter G, Sud M, Tognoni G, Gattinoni L
Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and
meta-analysis
Intensive Care Med 2010; 36: 585-599
Balconi G, Lehmann R, Fiordaliso F, Assmus B, Dimmeler S, Sarto P, Carbonieri E, Gualco A, Campana C, Angelici L,
Masson S, Mohammed SAA, Dejana E, Gorini M, Zeiher AM, Latini R, GISSI-HF Investigators
Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure
J Cardiac Fail 2009; 15: 747-755
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman
TM, Remuzzi G
Disruption of the Ang II type 1 receptor promotes longevity in mice
Pagina 9/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
J Clin Invest 2009; 119: 524-530
Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni
AP, Masson S, Vanasia M, de Simone G, on behalf of AREA IN-CHF Investigators
Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
Eur J Heart Fail 2009; 11: 68-76
Citerio G, Franzosi MG, Latini R, Masson S, Barlera S, Guzzetti S, Pesenti A
Anaesthesiological strategies in elective craniotomy: randomized, equivalence, open trial - The NeuroMorfeo trial
Trials 2009; 10: 19
Freel EM, Tsorlalis IK, Lewsey JD, Latini R, Maggioni AP, Solomon S, Pitt B, Connell JMC, McMurray JJV
Aldosterone status associated with insulin resistance in patients with heart failure - data from the ALOFT study
Heart 2009; 95: 1920-1924
Galvez BG, Covarello D, Tolorenzi R, Brunelli S, Dellavalle A, Crippa S, Mohammed SAA, Scialla L, Cuccovillo I, Molla
F, Staszewsky L, Maisano F, Sampaolesi M, Latini R, Cossu G
Human cardiac mesoangioblasts isolated from hypertrophic cardiomyopathies are greatly reduced in proliferation and
differentiation potency
Cardiovasc Res 2009, 83: 707-716
GISSI-AF Investigators (Writing Committee: Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP,
Lucci D, Di Pasquale G, Tognoni G),
Valsartan for prevention of recurrent atrial fibrillation
N Engl J Med 2009; 360: 1606-1617
Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB,
Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B,
Schultheiss H-P, Tschöpe C, Van Bilsen M, Zannad F, McMurray J, Shah AM
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of
the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail 2009; 11: 119-129
Latini L, Masson S
Biomarkers of myocyte injury in heart failure
Heart Fail Clin 2009; 5: 529-536
Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni
G, Tavazzi L, on behalf of the GISSI-HF Investigators
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial
Eur Heart J 2009; 30: 2327-2336
Maggioni AP, Franzosi MG, Latini R
Beta-adrenoceptor antagonists and antianginal drugs
In: Side effects of drugs, Annual 31
Elsevier, Amsterdam, 2009; 339-343
Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in
transgenic mouse models
J Clin Invest 2009; 119: 3356-3372
Marchioli R, Levantesi G, Silletta MG, Barlera S, Carbonieri E, Cosmi F, Franzosi MG, Latini R, Lucci D, Maggioni AP,
Moretti L, Nicolosi GL, Porcu M, Rossi MG, Tognoni G, Tavazzi L, on behalf of the GISSI-HF Investigators
Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial
Expert Rev Cardiovasc Ther 2009; 7: 735-748
Nobili A, Latini R
Interazioni pericolose in cardiologia
In: Cardiologia 2009. Atti del 43° convegno internazionale del dipartimento cardiologico A. De Gasperis. 28 settembre-2
ottobre 2009, Milano. Fond. Centro Cardiologia e Cardiochirurgia A. De Gasperis, Milano, 2009; 152-160
Pagina 10/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
Taccone P, Pesenti A, Latini R, Polli F, Vagginelli F, Mietto C, Caspani L, Raimondi F, Bordone G, Iapichino G, Mancebo
J, Guerin C, Ayzac L, Blanch L, Fumagalli R, Tognoni G, Gattinoni L, for the Prone-Supine II Study Group
Prone positioning in patients with moderate and severe acute respiratory distress syndrome. A randomized controlled trial
JAMA 2009, 302: 1977-1984
Amigoni M, Bellani G, Scanziani M, Masson S, Bertoli E, Radaelli E, Patroniti N, Di Lelio A, Pesenti A, Latini R
Lung injury and recovery in a murine model of unilateral acid aspiration: functional, biochemical, and morphologic
characterization
Anesthesiology 2008; 108: 1037-1046
Galvez BG, Sampaolesi M, Barbuti A, Crespi A, Covarello D, Brunelli S, Dellavalle A, Crippa S, Balconi G, Cuccovillo I,
Molla F, Staszewsky L, Latini R, DiFrancesco D, Cossu G
Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse
ventricle
Cell Death Differ 2008; 15: 1417-1428
Latini R
Cytokines and heart failure
Nova Acta Leopold 2008; n. 351: 27-31
Latini R, Brines M, Fiordaliso F
Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?
Heart Fail Rev 2008; 13: 415-423
Latini R, Masson S
Prognostic value of circulatory cardiac troponins in heart failure
Rev Esp Cardiol 2008; 61: 667-669
Latini R, Masson S
Il valore diagnostico della troponina T nell'insufficienza cardiaca
Recenti Prog Med 2008 99 : 505-508
Masson S, Latini R, Salio M. NT-proBNP and prognosis in chronic heart failure. In : NT-proBNP as a biomarker in
cardiovascular diseases Prous Science, Barcelona, 2008; 75-81
Maggioni AP, Franzosi MG, Latini R
Beta-adrenoceptor antagonists and antianginal drugs
In: Side effects of drugs, Annual 30 Elsevier, Amsterdam, 2008; 223-230
Masson S, Latini R
Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure
Am J Cardiol 2008; 101 Suppl: 56A-60A
Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn J N, for the Val-HeFT Investigators
Prognostic value of changes in N-termianl pro-brain natriuretic peptide in the Val-HeFT (Valsartan Heart Failure Trial)
J Am Coll Cardiol 2008; 52: 997-1003
McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J, for the Aliskiren
Observation of Heart Failure Treatment (ALOFT) Investigators
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure
Circulation Heart Failure 2008; 1: 17-24
Pedrazzini GB, Masson S, Latini R, Klersy C, Rossi M G, Pasotti E, Faletra FF, Siclari F, Minervini F, Moccetti T,
Auricchio A
Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late
postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis
Am J Cardiol 2008; 102: 749-754
Pedrazzini G, Santoro E, Latini R, Fromm L, Franzosi MG, Moccetti T, Staszewsky L, Barlera S, Tognoni G, Maggioni A
P, for the GISSI-3 Investigators
Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors:
Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial
Am Heart J 2008; 155: 388-394
Pagina 11/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010
GISSI-HF Investigators (Writing Committee: Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci
D, Nicolosi GL, Porcu M, Tognoni G)
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 2008; 372: 1223-1230
GISSI-HF Investigators (Writing Committee: Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci
D, Nicolosi GL, Porcu M, Tognoni G)
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial
Lancet 2008; 372: 1231-1239
1975-2007 more peer-reviewed articles, abstracts, book chapters.
Pagina 12/12 - Curriculum vitae di
Roberto Latini
Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010